Trials / Completed
CompletedNCT02357888
Assessment of V0018 2.5 mg Effect on Craving
Double-blind, Randomized, Placebo-controlled, Cross-over Study of the Effect of a 2.5 mg Nicotine Lozenge on Smoking Craving
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 45 (actual)
- Sponsor
- Pierre Fabre Medicament · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the reduction of craving and its time course after administration of V0018 2.5 mg compared to placebo in healthy highly dependant smokers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | V0018 | Oromucosal - Single dose |
| DRUG | Placebo | Oromucosal - Single dose |
Timeline
- Start date
- 2015-02-01
- Primary completion
- 2015-05-01
- Completion
- 2015-05-01
- First posted
- 2015-02-06
- Last updated
- 2015-10-08
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT02357888. Inclusion in this directory is not an endorsement.